Companies › SYRE
SPYRE THERAPEUTICS INC (SYRE)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001636282 · EDGAR filings · Updated 2026-07-02
SPYRE THERAPEUTICS INC (SYRE) has reported institutional ownership of 95.2%, with 198 institutional managers holding positions valued at $4.16B per the latest 13F reporting period. SEC filings include an active non-reliance notice on previously issued financial statements (8-K Item 4.02), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Latest updates
- 2026-07-02 — Insider transaction reported (Form 4)
- 2026-07-02 — Insider transaction reported (Form 4)
- 2026-07-02 — Insider transaction reported (Form 4)
- 2026-07-01 — Notice of proposed sale filed (Form 144)
- 2026-06-26 — Insider transaction reported (Form 4)
- 2026-06-26 — S-3ASR filed
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, SPYRE THERAPEUTICS INC has 198 institutional holders and institutional ownership of 95.2%.
Insider activity
Insiders reported 16 transactions (0 buys, 14 sells) across 3 reporting insiders, with a net reported value of −$3.47M.
Data flags from SEC filings
Related companies
ERASCA INC (ERAS) · RADNET INC (RDNT) · IRHYTHM HOLDINGS INC (IRTC) · LIGAND PHARMACEUTICALS INC (LGND) · Newamsterdam Pharma Co NV (NAMS) · SOTERA HEALTH CO (SHC)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-02.